Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2015

Comparison of the next-generation Xpert MRSA/SA BC assay and
the GeneOhm StaphSR assay to routine culture for identification
of Staphylococcus aureus and methicillin-resistant S. aureus in
positive-blood-culture broths
Blake W. Buchan
Medical College of Wisconsin

Stephen Allen
Indiana University - Purdue University Indianapolis

Carey-Ann D. Burnham
Washington University School of Medicine in St. Louis

Erin McElvania TeKippe
Washington University School of Medicine in St. Louis

Thomas Davis
Wishard Memorial Hospital
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
See next page for additional authors

Recommended Citation
Buchan, Blake W.; Allen, Stephen; Burnham, Carey-Ann D.; McElvania TeKippe, Erin; Davis, Thomas; Levi,
Michael; Mayne, Donna; Pancholi, Preeti; Relich, Ryan F.; Thomson, Richard; and Ledeboer, Nathan A.,
,"Comparison of the next-generation Xpert MRSA/SA BC assay and the GeneOhm StaphSR assay to
routine culture for identification of Staphylococcus aureus and methicillin-resistant S. aureus in positiveblood-culture broths." Journal of Clinical Microbiology. 53,3. 804-809. (2015).
https://digitalcommons.wustl.edu/open_access_pubs/3754

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Blake W. Buchan, Stephen Allen, Carey-Ann D. Burnham, Erin McElvania TeKippe, Thomas Davis, Michael
Levi, Donna Mayne, Preeti Pancholi, Ryan F. Relich, Richard Thomson, and Nathan A. Ledeboer

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/3754

Comparison of the Next-Generation Xpert MRSA/SA BC Assay and
the GeneOhm StaphSR Assay to Routine Culture for Identification of
Staphylococcus aureus and Methicillin-Resistant S. aureus in PositiveBlood-Culture Broths
Medical College of Wisconsin, Milwaukee, Wisconsin, USAa; Dynacare Laboratories, Milwaukee, Wisconsin, USAb; Indiana University School of Medicine, Indianapolis,
Indiana, USAc; Washington University School of Medicine, St. Louis, Missouri, USAd; Wishard Memorial Hospital, Indianapolis, Indiana, USAe; Montefiore Medical Center,
Bronx, New York, New York, USAf; Sacred Heart Hospital, Pensacola, Florida, USAg; The Ohio State University Wexner Medical Center, Columbus, Ohio, USAh; NorthShore
University HealthSystem, Evanston, Illinois, USAi

A bloodstream infection with Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), is a serious condition that
carries a high mortality rate and is also associated with significant hospital costs. The rapid and accurate identification and differentiation of methicillin-susceptible S. aureus (MSSA) and MRSA directly from positive blood cultures has demonstrated benefits in both patient outcome and cost-of-care metrics. We compare the next-generation Xpert MRSA/SA BC (Xpert) assay to the
GeneOhm StaphSR (GeneOhm) assay for the identification and detection of S. aureus and methicillin resistance in prospectively
collected blood culture broths containing Gram-positive cocci. All results were compared to routine bacterial culture as the gold
standard. Across 8 collection and test sites, the Xpert assay demonstrated a sensitivity of 99.6% (range, 96.4% to 100%) and a
specificity of 99.5% (range, 98.0% to 100%) for identifying S. aureus, as well as a sensitivity of 98.1% (range, 87.5% to 100%) and
a specificity of 99.6% (range, 98.3% to 100%) for identifying MRSA. In comparison, the GeneOhm assay demonstrated a sensitivity of 99.2% (range, 95.2% to 100%) and a specificity of 96.5% (range, 89.2% to 100%) for identifying S. aureus, as well as a sensitivity of 94.3% (range, 87.5% to 100%) and a specificity of 97.8% (range, 96.1% to 100%) for identifying MRSA. Five of six cultures falsely reported as negative for MRSA by the GeneOhm assay were correctly identified as positive by the Xpert assay, while
one culture falsely reported as negative for MRSA by the Xpert assay was correctly reported as positive by the GeneOhm assay.

B

loodstream infection (BSI) is a serious condition, resulting in
⬎500,000 hospitalizations per year in the United States, accounting for up to 11% of intensive care unit admissions (1, 2).
Mortality associated with BSI can range from 25% to 80%, depending on underlying illnesses, and it is higher in nosocomial
versus community-acquired infections (3–5). Bloodstream infections also carry a high monetary burden, ranging from $36,000 to
$40,000 in additional expenses per patient as a result of prolonged
hospitalization (4–6). The leading causes of community- and hospital-acquired BSI are Staphylococcus aureus, Staphylococcus epidermidis, and various other coagulase-negative Staphylococcus
(CoNS) species (5, 7). Within this group of organisms, infection
with methicillin-resistant S. aureus (MRSA) is most critical and
has been associated with a mortality rate 1.70 to 1.93 times higher
than that of methicillin-susceptible S. aureus (MSSA) strains (8,
9). The outcome of these infections can be positively impacted by
early diagnosis and effective antimicrobial therapy (10–12). Rapid
diagnostic methods, such as peptide nucleic acid fluorescence in
situ hybridization (PNA FISH), matrix-assisted laser desorption
ionization–time of flight mass spectrometry (MALDI-TOF MS),
and nucleic acid amplification and detection have been successfully applied to directly analyze positive blood culture broths (13–
17). These techniques reduce the time to the identification of
pathogens, including Staphylococcus spp., by 18 to 48 h compared
to that with conventional culture and biochemical identification
methods. The differentiation of S. aureus from CoNS (commonly
associated with culture contamination or inadequate skin preparation prior to specimen collection) in blood culture broths can
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result in a reduced length of hospital stay, vancomycin usage, and
overall cost of care (13). Further benefits in patient outcome and
cost of care can be achieved using nucleic acid amplification-based
tests to detect and differentiate MRSA from MSSA and CoNS (10).
This enables the optimization of antimicrobial therapy for MRSA
versus MSSA infections (12).
The molecular tests for identification of Staphylococcus spp.,
including MRSA, directly from positive blood culture broths include the GeneOhm StaphSR assay (BD, Sparks, MD), Verigene
BC-GP (Nanosphere, Northbrook, IL), FilmArray blood culture
identification (BCID) (BioFire, Salt Lake City, UT), and the Xpert
MRSA/SA BC assay (Cepheid, Sunnyvale, CA). Multiplexed assays, such as the Verigene BC-GP and FilmArray BCID, employ
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MATERIALS AND METHODS
Study enrollment. Eight clinical centers representing different geographic locations within the United States participated in a prospective
study to assess the clinical performance of the next-generation Xpert
MRSA/SA BC assay. Each center enrolled blood cultures using BD Bactec
Plus Aerobic/F (BD, Sparks, MD), VersaTREK REDOX 1 (Thermo
Fisher), or bioMérieux BacT/Alert SA Standard Aerobic (bioMérieux, Hazelwood, MO) medium. The cultures that were identified as positive by an
automated blood culture system were Gram stained to confirm the presence of bacteria. Cultures containing Gram-positive cocci as individual
cells or in clusters were considered for enrollment in the study. The specimens were tested using the next-generation Xpert MRSA/SA BC assay
and the GeneOhm assay, according to the product insert criteria for each
test. Only one blood culture per patient was enrolled to avoid duplicate
analysis of a single bacterial isolate. The study included blood cultures
obtained from both adult and pediatric patients; however, pediatric patients were not the focus of the study and comprised ⬍3% of the cultures
enrolled in the study. To avoid bias, the results from the molecular assays
were not known to the personnel conducting the reference culture
method testing. This study protocol was independently approved by the
institutional review board (IRB) at each clinical center.
Xpert MRSA/SA BC assay. For the Xpert MRSA/SA BC assay, blood
cultures containing Gram-positive cocci were tested within 24 h of culture
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positivity if held at room temperature or within 72 h if held at 2 to 8°C. A
50-l aliquot of the specimen was transferred to an elution reagent vial
(provided) and vortexed for 10 s. The entire contents of the elution reagent vial were then transferred to an Xpert MRSA/SA BC test cartridge,
which was sealed and inserted into the GeneXpert for analysis. The Xpert
MRSA/SA BC assay targets spa, mecA, and the SCCmec-orfX junction
using proprietary primer and probe sequences. The detection of all 3
targets was interpreted as positive for MRSA. If spa was detected alone or
in conjunction with SCCmec but mecA was not detected, the result was
interpreted as S. aureus (i.e., MSSA). If spa and mecA were detected in the
absence of the SCCmec-orfX junction, the result was also interpreted as S.
aureus (i.e., MSSA). If spa was not detected, the result was interpreted as
negative for S. aureus regardless of SCCmec-orfX and/or mecA being detected.
GeneOhm StaphSR assay. The blood cultures were tested within 48 h
of positivity using the GeneOhm assay. A 2-l aliquot of culture medium
was transferred to a sample buffer tube (provided) and vortexed for 10 s.
Fifty microliters of the homogenized mixture was transferred to a second
tube containing glass beads (provided), vortexed for 5 min to ensure lysis,
and heated to 95°C for 2 min. Following reconstitution, 25 l of reaction
master mix and 3 l of each lysed heat-inactivated sample were added to
individual SmartCycler PCR tubes. Real-time PCR was conducted in the
Cepheid SmartCycler II. The results were interpreted as positive for
MRSA, positive for S. aureus, or negative based upon the detection of
amplicon corresponding to SCCmec-orfX and/or proprietary S. aureusspecific genetic targets. The specimens generating invalid results (i.e., a
reading of “invalid,” “error,” “no result,” or “unresolved”) on either assay
were repeated once. The specimens generating a second invalid result
were excluded from statistical analysis.
Reference culture method. The blood culture broths were plated to
agar medium containing 5% sheep blood and incubated for 18 to 48 h.
Beta-hemolytic colonies were identified as S. aureus using Gram stain
morphology, a positive catalase test, and positive S. aureus latex agglutination (BactiStaph; Remel, Lenexa, KS). All isolates identified as S. aureus
were tested for oxacillin/methicillin resistance using the cefoxitin disk
diffusion method in accordance with Clinical and Laboratory Standards
Institute (CLSI) standards M02-A11 (24) and M100-S22 (25). In brief, a
0.5 McFarland suspension of the test strain was plated on Mueller-Hinton
agar (MHA). A 30-g cefoxitin disk was placed onto the plate, and the
culture was incubated aerobically for 16 to 18 h at 35°C, at which point the
zone of inhibition was measured and interpreted (ⱕ21 mm, resistant;
ⱖ22 mm, susceptible).
Data analysis. The results for each of the molecular assays were compared to those of the reference culture and antimicrobial susceptibility
testing methods. The sensitivities and specificities were calculated using
standard methods. The 95% confidence interval was determined using the
binomial expansion method. The poolability of the data between sites was
examined using Fisher’s exact test. If P values were ⬍0.05, the difference
between the groups was considered to be statistically significant. The statistical significance between the performance (sensitivity and specificity)
of each assay was established using McNemar’s test (26).

RESULTS

Study population. A total of 795 blood culture broths (468 BD
Bactec Plus Aerobic/F sites A, B, C, F, and H; 197 VersaTREK
REDOX 1 sites D and G; and 130 BacT/Alert SA Standard Aerobic
site E) meeting the study criteria were collected and tested at 8
clinical centers using the Xpert MRSA/SA BC assay. The prevalences based on culture-confirmed results were 29.7% (range,
20.8% to 38.6%) for S. aureus and 13.3% (range, 7.0% to 17.6%)
for MRSA. The Xpert MRSA/SA BC assay successfully returned
results for 764/795 broths (96.1%) following the initial test. This
increased to 792/795 (99.6%) broths following a single retest of
the specimens initially reported to be invalid, error, or no result. A
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separate probes for detecting S. aureus and mecA, the gene that
confers resistance to methicillin. This approach has proven to be
sensitive for detecting MRSA; however, the independent detection
of these markers can result in false-positive results when a culture
contains both MSSA and a methicillin-resistant CoNS (MRCoNS) (14, 18). In contrast, more traditional real-time PCR (RTPCR)-based assays, including the GeneOhm StaphSR and Xpert
MRSA/SA BC assays, target the junction of the staphylococcal
cassette chromosome mec element (SCCmec) (a chromosomal
cassette harboring mecA) and orfX in order to specifically identify
MRSA. A benefit to this approach is the ability to discriminate
MRSA from S. aureus and MR-CoNS in mixed cultures. The
Xpert MRSA/SA BC assay contains additional primers and probes
to ensure that mecA is present, reducing the chance of a falsepositive result. Initial evaluations of the performance of the
GeneOhm and Xpert MRSA/SA BC assays reported 98.3% to
100% sensitivity and 98.4% to 99.4% specificity for the identification of MRSA (17, 19). A drawback to the use of a surrogate
marker (SCCmec-orfX) for identifying MRSA is the potential for
genetic rearrangements or point mutations that affect either the
SCCmec-orfX primer binding sites or the mecA gene itself, which
can result in false-negative results. Recent studies using pure cultures of previously characterized isolates have reported sensitivities as low as 50% to 92% for identifying MRSA in simulated blood
cultures, many of which contained the mecC determinant, or as a
result of variant SCCmec types or genetic rearrangements/deletions within the SCCmec cassette (20–23).
We compared the performance of the next-generation Xpert
MRSA/SA BC assay (Xpert) to that of the GeneOhm StaphSR
assay for identifying and detecting S. aureus and methicillin resistance in prospectively collected blood culture broths containing
Gram-positive cocci. The new Xpert MRSA/SA BC assay cartridge
contains all the reagents required to run the assay on-board, and
the time to results is approximately 10 min longer due to changes
in the automated sample processing. The two molecular tests were
compared to routine culture and identification methods using
latex agglutination and cefoxitin disk diffusion tests as the reference method.

Buchan et al.

TABLE 1 Performances of Xpert MRSA/SA BC and GeneOhm StaphSR assays for detection of S. aureus compared to that of routine culture method
No. with resulta:
FP

TN

FN

Sensitivity (%
[95% CI])b

Specificity (%
[95% CI])

63
91
44
70
130
211
126
57
792

19
32
17
26
27
65
31
18
235

0
0
0
0
2c
1e
0
0
3

44
59
27
44
100
145
95
39
553

0
0
0
0
1d
0
0
0
1

100 (82.4–100)
100 (89.1–100)
100 (80.5–100)
100 (86.8–100)
96.4 (79.7–99.8)
100 (94.5–100)
100 (88.8–100)
100 (81.5–100)
99.6 (97.7–99.9)

100 (92.0–100)
100 (93.9–100)
100 (87.2–100)
100 (92.0–100)
98.0 (92.4–99.6)
99.3 (96.2–100)
100 (96.2–100)
100 (91.0–100)
99.5 (98.4–99.9)

60
91
52
63
131
202
127
56
782

18
32
20
25
28
64
30
17
234

0
2
1
0
4
8
0
4
19

42
57
30
38
99
130
96
30
527

0
0
1
0
0
0
1d
0
2

100 (81.5–100)
100 (89.1–100)
95.2 (76.2–99.9)
100 (86.3–100)
100 (87.7–100)
100 (94.4–100)
96.8 (83.3–99.9)
100 (80.5–100)
99.2 (97.0–99.9)

100 (91.6–100)
96.6 (88.3–99.6)
96.8 (73.2–95.8)
100 (90.7–100)
96.1 (90.4–98.9)
94.2 (88.9–97.5)
100 (96.2–100)
89.7 (75.8–97.1)
96.5 (94.6–97.9)

Site

Xpert MRSA/SA BC

A
B
C
D
E
F
G
H
Total

GeneOhm StaphSR

A
B
C
D
E
F
G
H
Total

a

TP, true positive; FP, false positive; TN, true negative; FN, false negative.
CI, confidence interval.
c
1 identified as MRSA and 1 identified as S. aureus (MSSA) by the Xpert MRSA/SA BC assay.
d
Identified as MSSA by culture.
e
Identified as S. aureus (MSSA) by the Xpert MRSA/SA BC assay.
b

total of 806 specimens (474 BD Bactec Plus Aerobic/F, 197 VersaTREK REDOX 1, and 135 BacT/Alert SA Standard Aerobic) were
tested using the GeneOhm assay and reference culture, according
to the study criteria. The GeneOhm assay generated a valid result
for 776/806 (96.3%) specimens on the initial test. A single repeat
test was conducted with 21/30 samples that failed the initial analysis, of which 6 generated a valid result. The remaining 9 samples
with an initial invalid result were not retested within the time
frame specified by the product insert. This resulted in a final valid
result rate of 782/797 (98.1%).
Identification of S. aureus. The two molecular tests demonstrated similar sensitivities (Xpert, 99.6%; GeneOhm, 99.2%; P ⫽
0.99 to 1.00, Fisher’s exact test) for identifying S. aureus (MRSA
and MSSA) in blood culture broths (Table 1). The sensitivities of
the molecular tests ranged from 95.2% to 100% among the 8 clinical centers; however, the intersite variability for each test was not
statistically significant (P ⬎ 0.05, Fisher’s exact test). Additionally,
there was not a statistically significant difference in performance
between the three blood culture systems used by the various study
sites. One sample tested falsely negative for S. aureus by the Xpert
assay but it tested positive by the GeneOhm assay (Table 1, site E).
Two samples tested falsely negative by the GeneOhm assay but
were positive for S. aureus by the Xpert assay (Table 1, sites C and
G). The specificity of the Xpert test was 99.5% (553/556), with
three false-positive S. aureus results reported. All three specimens
were also reported as either positive (i.e., MRSA) or reactive (i.e.,
S. aureus) by the GeneOhm assay, all of which matched the corresponding Xpert assay results. The GeneOhm assay was comparatively less specific (96.5% [527/546]), reporting 19 false-positive S.
aureus results (P ⬍ 0.001).
Identification of MRSA. The identification of MRSA in
blood culture broths showed greater variability between the 2
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molecular tests (Table 2). The sensitivity of the Xpert assay was
a combined 98.1% (103/105), while the sensitivity of the
GeneOhm assay was 94.3% (99/105). The sensitivity of the
Xpert assay ranged from 87.5% to 100% across the eight clinical centers but was a combined 100% (77/77) at six of the eight
clinical centers. This intersite variability was not statistically
significant (P ⬎ 0.05, Fisher’s exact test), nor was there a statistically significant difference in performance between the culture media. Across all test sites, the Xpert assay reported two
blood cultures to be S. aureus that were confirmed to be MRSA by
the cefoxitin disk diffusion test (i.e., false-negative Xpert assay
results). Also, one of two blood cultures was negative for MRSA by
the GeneOhm assay (Table 3, specimen C039), while the other
tested positive (Table 3, specimen G013). Of note, specimen G013
was reported to contain MRSA by reference culture, while specimen C039 was reported to contain both MRSA and MSSA. Across
5 test sites, GeneOhm assay reported 6 cultures to be negative for
MRSA, for a combined sensitivity of 94.3% (range, 87.5% to
100%). All 6 false-negative reports were had a positive result for S.
aureus by the GeneOhm assay only, but 5/6 tested positive for
MRSA by the Xpert assay (Table 3).
The specificity of the Xpert assay for identifying MRSA was
⬎99.6% (684/687), with 3 false-positive results across all 8 test
sites (Table 2). Two of these results were obtained from blood
cultures containing methicillin-susceptible S. aureus; however,
one sample was negative for S. aureus by reference culture, indicating possible contamination or the presence of a nonviable organism. The specificity of the GeneOhm assay was 97.8% (662/
677). Of the 15 false-positive results for MRSA, 7 blood cultures
contained methicillin-susceptible S. aureus, and 9 were negative
for S. aureus by reference culture.
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TP

Test

Total no. of
specimens tested

Next-Generation Xpert MRSA/SA BC Assay

TABLE 2 Performances of Xpert MRSA/SA BC and GeneOhm StaphSR assays for detection of MRSA compared to that of routine culture method
No. with resulta:
FP

TN

FN

Sensitivity
(% [95% CI])b

Specificity
(% [95% CI])

63
91
44
70
130
211
126
57
792

11
16
7
11
10
25
19
4
103

0
0
0
1c
1d
1c
0
0
3

52
75
36
58
119
185
106
53
684

0
0
1
0
0
0
1
0
2e

100 (71.5–100)
100 (79.4–100)
87.5 (47.3–99.7)
100 (71.5–100)
100 (69.2–100)
100 (86.3–100)
95.0 (73.0–99.7)
100 (81.5–100)
98.1 (93.3–99.8)

100 (93.2–100)
100 (95.2–100)
100 (90.3–100)
98.3 (90.9–100)
99.2 (95.4–100)
99.5 (97.0–100)
100 (96.2–100)
100 (91.6–100)
99.6 (98.7–99.9)

60
91
52
63
131
202
127
56
782

10
14
8
10
10
24
19
4
99

0
1d
1c
0
3f
7g
1c
2h
15

49
74
42
53
118
170
106
50
662

1
2
1
0
0
1
1
0
6i

90.9 (58.7–99.8)
87.5 (61.7–98.4)
88.9 (51.8–99.7)
100 (69.2–100)
100 (69.2–100)
96.0 (79.6–99.9)
95.0 (75.1–99.9)
100 (39.8–100)
94.3 (88.0–97.9)

100 (96.4–98.8)
98.7 (92.8–100)
97.7 (87.7–99.9)
100 (93.3–100)
97.5 (92.9–99.5)
96.1 (92.0–98.4)
99.1 (94.9–100)
96.2 (86.8–99.5)
97.8 (96.4–98.8)

Site

Xpert MRSA/SA BC

A
B
C
D
E
F
G
H
Total

GeneOhm StaphSR

A
B
C
D
E
F
G
H
Total

a

TP, true positive; FP, false positive; TN, true negative; FN, false negative.
CI, confidence interval.
c
Identified as MSSA by culture.
d
Negative for S. aureus by culture.
e
Identified as S. aureus (MSSA) by the Xpert MRSA/SA BC assay.
f
One identified as S. aureus (MSSA), and two negative for S. aureus by culture.
g
Two identified as S. aureus (MSSA), and five negative for S. aureus by culture.
h
One identified as S. aureus (MSSA), and one negative for S. aureus by culture.
i
Identified as S. aureus (MSSA) by GeneOhm assay.
b

DISCUSSION

The next-generation Xpert MRSA/SA BC assay is an on-demand
sample-to-result molecular test for the identification of S. aureus
and MRSA directly from positive blood culture broths. The detection and differentiation of S. aureus and MRSA are achieved by
incorporating three nucleic acid targets, including the SCCmecorfX junction, mecA, and spa. The BD GeneOhm StaphSR test uses
a two-target approach, relying on the detection of the SCCmecorfX junction site and an S. aureus species-specific target for the
identification of MRSA (17). The initial clinical evaluations of the
original Xpert MRSA/SA BC assay and the GeneOhm StaphSR test

TABLE 3 Specimens resulting in false-negative MRSA calls by the Xpert
MRSA/SA BC and/or GeneOhm StaphSR assay
Specimen
IDa

Zone diam
(mm)b

Xpert MRSA/SA
BC assay resultc

GeneOhm
StaphSR
assay result

A004
B042
B080
C039
F094
G013
G022

None
8
7
12, 26d
10
6
6

TP
TP
TP
FN
TP
FN
TP

FN
FN
FN
FN
FN
TP
FN

a

ID, identification.
Zone of inhibition measured by cefoxitin disk diffusion test.
c
TP, true positive; FN, false negative.
d
Specimen contained two isolates of S. aureus. One MRSA and one MSSA (showing
12-mm and 26-mm zones of inhibition for cefoxitin, respectively).
b

March 2015 Volume 53 Number 3

demonstrated sensitivities of 93.7% to 100% for S. aureus and
98.3% to 100% for MRSA in positive blood culture broths (17, 19,
27). Subsequently, several published reports indicated sensitivities
as low as 50% to 92% for detecting MRSA using the GeneOhm and
Xpert MRSA/SA assays (20–23). These false-negative results were
primarily attributable to mutations in the junction region of
SCCmec-orfX, the target of the GeneOhm assay, or to variant
SCCmec types, including type IVa, which in some institutions
comprise up to 33% of the SCCmec types (20, 22, 23, 28). Additionally, the specificities of these tests for identifying MRSA suffer
for strains containing truncated SCCmec cassettes or “empty cassettes” lacking a functional mecA gene (29, 30). Such strains may
account for up to 4.6% of the S. aureus strains carrying the cassette
(28).
The Next-generation Xpert MRSA/SA BC assay incorporates a
modified sample preparation protocol to improve assay accuracy,
although the specific changes to the assay are not publicly available. Though not statistically significant, the Xpert MRSA/SA BC
assay demonstrated greater sensitivity than that of the GeneOhm
StaphSR test for identifying MRSA. One of the two false-negative
results reported by the Xpert assay contained both MSSA and
MRSA upon reference culture, and the GeneOhm assay also failed
to identify MRSA in this specimen. Taken together, this might
suggest contamination of the reference culture with MRSA subsequent to molecular testing. The specificity of the Xpert MRSA/SA
BC assay was ⬎99.5% for both S. aureus and MRSA, which is equal
to or greater than that of the GeneOhm assay. The three specimens
with false-positive results for S. aureus by the Xpert assay were also
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TP

Test

Total no. of
specimens tested
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lends to batch processing, these tests may have been initiated after
the initiation of the Xpert test. It is possible that delayed testing
negatively impacts results if the specimen contained nucleases that
degrade target sequences or accumulated other inhibitory substances resulting from specimen degradation. Alternatively, delayed testing may increase sensitivity due to additional bacterial
growth. These factors were not evaluated; however, both molecular tests were performed according to the specimen acceptability
criteria set forth in the respective product insert.
The benefits of the rapid detection of S. aureus and MRSA
directly from positive blood culture broths are well documented.
Specifically, molecular testing for S. aureus and MRSA resulted in
a 21% decrease in the number of patients receiving anti-MRSA
therapy and a mean reduction of 12.2 h in the duration of therapy
for patients with blood cultures containing Gram-positive cocci
that tested negative for S. aureus (36). Likewise, the time to optimal antimicrobial therapy for the patients with cultures positive
for MSSA was reduced by 38.4 to 44.6 h following the implementation of a molecular test (10, 36). These rapid results contributed
to a mean reduction in the length of hospital stay of 6.2 days and a
reduction of $21,387 in the total hospital cost per septic episode
compared to those of patients diagnosed using routine culture and
susceptibility testing methods (10). Importantly, these advantages
are realized only when molecular testing can be performed ondemand and the results are actively reported to the clinician. The
use of batched testing formats and passive reporting of results does
not significantly reduce the time to optimal antimicrobial therapy
despite definitive identification of S. aureus and MRSA ⬃13 h
sooner than with culture methods (37). The Xpert and GeneOhm
assays demonstrated statistically equivalent sensitivities and specificities for identifying S. aureus and MRSA in positive blood cultures compared to those with the culture method. A potential
advantage of the Xpert MRSA/SA BC assay is the simplified sample-to-result workflow and on-demand capability, which gives it
the potential to reduce the turnaround time for blood cultures
containing S. aureus or MRSA.
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